<p>Fortress Biotech Inc ((FBIO)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>Fortress Biotech Inc 最近的财报电话会议描绘了强劲增长和乐观的前景，尽管面临一些挑战。公司庆祝了显著的收入增长，这得益于 EMROSI 的成功推出，该产品在市场上表现出良好的结果。然而，诸如传统产品收入下降和 EMROSI 在健康计划目录中的采用延迟等挑战也得到了认可。总体而言，情绪是积极的，大家对 EMROSI 的潜力和未来收入增长充满信心。</p>
<h2>显著的收入增长</h2>
<p>Fortress Biotech 的子公司 Journey Medical 报告称，2025 年第三季度的收入同比增长了 21%，达到了 1760 万美元，较去年同期的 1490 万美元有所上升。这一增长凸显了公司成功的战略和市场渗透。</p>
<h2>EMROSI 的强劲表现</h2>
<p>EMROSI 作为公司治疗玫瑰痤疮的口服药物，对收入贡献显著，第三季度为公司增加了 490 万美元的收入。这比上一季度增长了 75%，总处方增长约 146%，突显了该产品在市场上的强大接受度和潜力。</p>
<h2>积极的 EBITDA 趋势</h2>
<p>公司报告称非 GAAP EBITDA 改善，同比增加了 50 万美元。2025 年第三季度的调整后 EBITDA 为 170 万美元，而 2024 年第三季度为 30 万美元，反映出运营效率和财务健康的改善。</p>
<h2>EMROSI 的开处方医生数量增加</h2>
<p>EMROSI 的独立开处方医生数量增加了约 50%，超过 2700 名。这表明皮肤科医生的采用率强劲，增强了该产品的市场存在感。</p>
<h2>市场准入成就</h2>
<p>Journey Medical 实现了显著的市场准入，超过 1 亿的 1.87 亿商业人群可以使用 EMROSI。公司计划在明年初与剩余的主要团体采购组织签约，进一步扩大其覆盖范围。</p>
<h2>传统产品收入下降</h2>
<p>来自传统产品如 Qbrexza、Accutane、Amzeeq 和 Zilxi 的收入同比下降了 16%。这一下降归因于仿制药竞争，特别是对 Accutane 的影响。</p>
<h2>毛利率略有下降</h2>
<p>2025 年第三季度的毛利率略微下降至 67.4%，而去年为 69.4%。这主要是由于产品组合的变化，反映出市场动态的演变。</p>
<h2>健康计划目录采用的挑战</h2>
<p>EMROSI 在健康计划目录中的采用进展缓慢，影响了即时覆盖。这增加了对共付援助计划的依赖，给公司的短期财务战略带来了挑战。</p>
<h2>前瞻性指导</h2>
<p>Journey Medical 对未来的指导依然乐观，得益于 EMROSI 的成功推出。公司预计到第四季度将实现可持续的 EBITDA 正增长，并预计 EMROSI 在美国的年净销售额将超过 2 亿美元，全球超过 3 亿美元。对支付者战略和市场准入的战略关注预计将继续支持收入增长。</p>
<p>总之，Fortress Biotech 的财报电话会议反映出积极的前景，强劲的收入增长和 EMROSI 的良好表现。尽管面临传统产品收入下降和目录采用延迟等挑战，公司对未来前景依然充满信心，得益于战略举措和市场扩展努力。</p>

FBIO

<p>Fortress Biotech 的第三季度财报电话会议强调了由于 EMROSI 的成功而带来的显著收入增长，尽管面临着传统产品收入下降和处方采用延迟等挑战。Journey Medical 报告了 21% 的收入增长，其中 EMROSI 贡献了 490 万美元。该公司改善了 EBITDA 并扩大了市场准入。尽管毛利率略有下降，Fortress Biotech 仍然保持乐观，预计到第四季度将实现可持续的 EBITDA 正增长，并预计 EMROSI 在美国的年净销售额将超过 2 亿美元，全球超过 3 亿美元</p>

<p>Fortress Biotech Inc ((FBIO)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Fortress Biotech Inc ((FBIO)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>Fortress Biotech Inc’s recent earnings call painted a picture of robust growth and optimism, despite some hurdles. The company celebrated significant revenue growth, driven by the successful launch of EMROSI, which has shown promising results in the market. However, challenges such as declining legacy product revenues and delays in health plan formulary adoption for EMROSI were also acknowledged. Overall, the sentiment was positive, with a strong belief in EMROSI’s potential and future revenue growth.</p>
<div class="lb-trans"><p>Fortress Biotech Inc 最近的财报电话会议描绘了强劲增长和乐观的前景，尽管面临一些挑战。公司庆祝了显著的收入增长，这得益于 EMROSI 的成功推出，该产品在市场上表现出良好的结果。然而，诸如传统产品收入下降和 EMROSI 在健康计划目录中的采用延迟等挑战也得到了认可。总体而言，情绪是积极的，大家对 EMROSI 的潜力和未来收入增长充满信心。</p>
</div><h2>Significant Revenue Growth</h2>
<div class="lb-trans"><h2>显著的收入增长</h2>
</div><p>Journey Medical, a subsidiary of Fortress Biotech, reported a remarkable 21% year-over-year revenue growth for the third quarter of 2025. The revenue reached $17.6 million, up from $14.9 million in the same quarter of the previous year. This growth underscores the company’s successful strategies and market penetration.</p>
<div class="lb-trans"><p>Fortress Biotech 的子公司 Journey Medical 报告称，2025 年第三季度的收入同比增长了 21%，达到了 1760 万美元，较去年同期的 1490 万美元有所上升。这一增长凸显了公司成功的战略和市场渗透。</p>
</div><h2>EMROSI’s Strong Performance</h2>
<div class="lb-trans"><h2>EMROSI 的强劲表现</h2>
</div><p>EMROSI, the company’s oral treatment for rosacea, contributed significantly to the revenue, adding $4.9 million to the top line in Q3. This marks a 75% increase from the previous quarter, with total prescription growth of approximately 146%, highlighting the product’s strong market acceptance and potential.</p>
<div class="lb-trans"><p>EMROSI 作为公司治疗玫瑰痤疮的口服药物，对收入贡献显著，第三季度为公司增加了 490 万美元的收入。这比上一季度增长了 75%，总处方增长约 146%，突显了该产品在市场上的强大接受度和潜力。</p>
</div><h2>Positive EBITDA Trends</h2>
<div class="lb-trans"><h2>积极的 EBITDA 趋势</h2>
</div><p>The company reported an improvement in non-GAAP EBITDA, which increased by $500,000 year-over-year. The adjusted EBITDA for Q3 2025 was $1.7 million, compared to $300,000 in Q3 2024, reflecting improved operational efficiency and financial health.</p>
<div class="lb-trans"><p>公司报告称非 GAAP EBITDA 改善，同比增加了 50 万美元。2025 年第三季度的调整后 EBITDA 为 170 万美元，而 2024 年第三季度为 30 万美元，反映出运营效率和财务健康的改善。</p>
</div><h2>Increased Prescriber Base for EMROSI</h2>
<div class="lb-trans"><h2>EMROSI 的开处方医生数量增加</h2>
</div><p>The number of unique prescribers for EMROSI increased by approximately 50%, reaching over 2,700. This indicates a strong adoption rate among dermatologists and enhances the product’s market presence.</p>
<div class="lb-trans"><p>EMROSI 的独立开处方医生数量增加了约 50%，超过 2700 名。这表明皮肤科医生的采用率强劲，增强了该产品的市场存在感。</p>
</div><h2>Market Access Achievements</h2>
<div class="lb-trans"><h2>市场准入成就</h2>
</div><p>Journey Medical has achieved significant market access, with over 100 million of the 187 million commercial lives having access to EMROSI. The company plans to contract with the remaining major group purchasing organizations early next year, further expanding its reach.</p>
<div class="lb-trans"><p>Journey Medical 实现了显著的市场准入，超过 1 亿的 1.87 亿商业人群可以使用 EMROSI。公司计划在明年初与剩余的主要团体采购组织签约，进一步扩大其覆盖范围。</p>
</div><h2>Decline in Legacy Product Revenues</h2>
<div class="lb-trans"><h2>传统产品收入下降</h2>
</div><p>Revenues from legacy products like Qbrexza, Accutane, Amzeeq, and Zilxi declined by 16% year-over-year. This decline is attributed to generic competition, particularly impacting Accutane.</p>
<div class="lb-trans"><p>来自传统产品如 Qbrexza、Accutane、Amzeeq 和 Zilxi 的收入同比下降了 16%。这一下降归因于仿制药竞争，特别是对 Accutane 的影响。</p>
</div><h2>Slight Decrease in Gross Margin</h2>
<div class="lb-trans"><h2>毛利率略有下降</h2>
</div><p>The gross margin slightly decreased to 67.4% in Q3 2025 from 69.4% in the previous year. This was primarily due to changes in product mix, reflecting the evolving market dynamics.</p>
<div class="lb-trans"><p>2025 年第三季度的毛利率略微下降至 67.4%，而去年为 69.4%。这主要是由于产品组合的变化，反映出市场动态的演变。</p>
</div><h2>Challenges with Health Plan Formulary Adoption</h2>
<div class="lb-trans"><h2>健康计划目录采用的挑战</h2>
</div><p>EMROSI’s adoption into health plan formularies is progressing slowly, impacting immediate coverage. This has increased reliance on the co-pay assistance program, posing a challenge to the company’s short-term financial strategy.</p>
<div class="lb-trans"><p>EMROSI 在健康计划目录中的采用进展缓慢，影响了即时覆盖。这增加了对共付援助计划的依赖，给公司的短期财务战略带来了挑战。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Journey Medical’s guidance for the future remains optimistic, driven by the successful launch of EMROSI. The company expects to become sustainably EBITDA positive by Q4 and anticipates peak annual net sales of over $200 million in the U.S. and over $300 million globally for EMROSI. The strategic focus on payer strategy and market access is expected to continue supporting revenue growth.</p>
<div class="lb-trans"><p>Journey Medical 对未来的指导依然乐观，得益于 EMROSI 的成功推出。公司预计到第四季度将实现可持续的 EBITDA 正增长，并预计 EMROSI 在美国的年净销售额将超过 2 亿美元，全球超过 3 亿美元。对支付者战略和市场准入的战略关注预计将继续支持收入增长。</p>
</div><p>In summary, Fortress Biotech’s earnings call reflected a positive outlook with strong revenue growth and promising performance from EMROSI. Despite challenges such as declining legacy product revenues and formulary adoption delays, the company remains optimistic about its future prospects, driven by strategic initiatives and market expansion efforts.</p>
<div class="lb-trans"><p>总之，Fortress Biotech 的财报电话会议反映出积极的前景，强劲的收入增长和 EMROSI 的良好表现。尽管面临传统产品收入下降和目录采用延迟等挑战，公司对未来前景依然充满信心，得益于战略举措和市场扩展努力。</p>
</div>

Fortress Biotech 的财报电话会议突出了 EMROSI 的成功